A delayed clinical trial actually boosted Bristol Myers Squibb’s stock. Here’s why.

3 weeks ago 7

ARTICLE AD BOX

Bristol Myers’ stock rallied Wednesday as investors maintained high hopes for Cobenfy as an Alzheimer’s treatment, even though the outcome of a late-stage trial has been delayed.

Read Entire Article

A delayed clinical trial actually boosted Bristol Myers Squibb’s stock. Here’s why.

ARTICLE AD BOX

Related

Trump Media just launched 5 ‘Made in America’ ETFs, testing ...

Buying bitcoin is no longer a thing for this David Beckham-b...

Interest rates could be on hold ‘for some time,’ Fed minutes...

Trending

Popular

Can Pidcock win big & why did it end at Ineos?

‘I didn’t want to spend time with my children. I was just go...

‘Slanted’ Review: Extreme Makeover Satire Critiques Lopsided...

Netflix scuttles plans to add six previously announced games...

OpenAI co-founder John Schulman has left Anthropic after les...